Значения термина operable breast на английском

Results: Twenty-two of the 227 young women with primary operable breast cancer had PA cancer.

Neoadjuvant systemic therapy is used to enable breast-conserving surgery in patients with large primary operable breast cancers.

Primary (neoadjuvant) chemotherapy is a rapidly evolving area in the management of early operable breast cancer.

The literature reports low rates of breast conservation after neoadjuvant chemotherapy for operable breast cancers not amenable to initial breast-conserving surgery.

Conclusions: A 2-month weekly treatment with PET represents a well tolerated and highly effective approach in large operable breast cancer patients.

Primary systemic therapy (PST) for operable breast cancer enables the identification of in vivo biological markers that predict response to treatment.

From June 1973 to May 1978 a total of 845 patients with operable breast cancer were entered into different adjuvant programs.

Purpose: To evaluate in a randomized clinical trial systemic chemoendocrine therapy used as primary (neo-adjuvant) treatment before surgery in women with primary operable breast cancer.

Between 1974 and 1982, 796 patients with operable breast cancer following local therapy were treated with 3 consecutive doxorubicin-containing adjuvant therapy trials.

Significantly higher protein expression was observed for Pgp, Ki-67 and p53 in the locally advanced breast cancers than in primary operable breast cancers.

Infusional ECF has shown a response rate of 98%, with 66% complete remissions, in a trial involving 50 women with large operable breast tumors.